Business Context and Reporting Period
Company: Gyre Therapeutics, Inc. (GYRE)
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2026
Event: Entry into a Material Definitive Agreement to acquire Cullgen Inc.
Key Financial Metrics and Transaction Terms
Transaction Value: Approximately $300 million (all-stock transaction).
Exchange Ratio: 0.4753 shares of Gyre Common Stock (or equivalent Preferred Stock) for each share of Cullgen Common Stock, subject to a 5:1 conversion adjustment for certain holders.
Capital Structure Impact: Gyre will issue Series B Convertible Preferred Stock to certain designated holders and Common Stock to other holders. The issuance is capped at 19.99% of Gyre's issued and outstanding Common Stock or voting power prior to stockholder approval of the Conversion Proposal.
Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for either company.
Material Changes and Corporate Actions
- Merger Structure: Gyre will acquire Cullgen via a merger with Helix Merger Sub Corp., a wholly-owned subsidiary of Gyre. Cullgen will survive as a wholly-owned subsidiary.
- Tax Status: The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
- Equity Conversion: Outstanding in-the-money Cullgen options will convert to Gyre options; out-of-the-money options will be cancelled. Restricted stock units will vest and settle into Gyre Common Stock.
- Board Changes:
- Resignations: Thomas Eastling and Songjiang Ma will resign from the Board and Mr. Ma will resign as President immediately prior to the Effective Time.
- Appointments: Ying Luo, Ph.D. (current CEO of Cullgen) will be appointed CEO, President, and Class I Director of Gyre immediately after the Effective Time.
Guidance, Outlook, Risks, and Contingencies
Conditions to Closing:
- Approval by requisite Cullgen stockholders.
- Expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act.
- Accuracy of representations and warranties and performance of obligations by both parties.
Stockholder Approval Requirements:
- Gyre stockholders must approve the "Conversion Proposal" to convert the Series B Preferred Stock into Common Stock.
- Cullgen stockholders must approve the Merger Agreement.
Lock-Up Agreements: Certain officers, directors, and stockholders of both companies have agreed to lock-up periods of 180 days, 12 months, and 18 months (in thirds) following the Merger Closing Date.
Risks and Forward-Looking Statements: The filing contains forward-looking statements regarding the closing of the Merger and regulatory approvals. These are subject to risks and uncertainties, including the failure to obtain necessary approvals or the accuracy of assumptions regarding future performance. No assurance is given that the Merger will be completed.
Investor Verification Checklist
- Merger Agreement Details: Review Exhibit 2.1 for specific termination rights, representations, and warranties.
- Preferred Stock Terms: Examine the Certificate of Designation (Exhibit 3.1) for voting rights, dividend provisions, and conversion limitations of the Series B Convertible Preferred Stock.
- Stockholder Votes: Monitor upcoming proxy statements for the specific voting thresholds required for the Conversion Proposal and Merger approval.
- Regulatory Status: Verify the status of the HSR filing and any other regulatory approvals required for closing.
- Management Transition: Confirm the effective date of Dr. Ying Luo's appointment as CEO and the departure of current leadership.